SEC Comment Letter for Armata Pharmaceuticals, Inc. (ARMP) (CIK 0000921114) (ARMP) — Aug 28, 2018
Armata Pharmaceuticals, Inc. (ARMP) (CIK 0000921114)
Date: Aug. 28, 2018 · CIK: 0000921114 · Accession: 0000000000-18-026766
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-226959
Letter
August 28, 2018 Steve Martin Chief Financial Officer AmpliPhi Biosciences Corp 3579 Valley Centre Drive, Suite 100 San Diego, CA 92130 Re:AmpliPhi Biosciences Corp Registration Statement on Form S-1 Filed August 21, 2018 File No. 333-226959 Dear Mr. Martin: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Dorrie Yale at 202-551-8776 with any questions. Sincerely, Division of Corporation Finance Office of Healthcare & Insurance cc: James Pennington
Show Raw Text
August 28, 2018
Steve Martin
Chief Financial Officer
AmpliPhi Biosciences Corp
3579 Valley Centre Drive, Suite 100
San Diego, CA 92130
Re:AmpliPhi Biosciences Corp
Registration Statement on Form S-1
Filed August 21, 2018
File No. 333-226959
Dear Mr. Martin:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Dorrie Yale at 202-551-8776 with any questions.
Sincerely,
Division of Corporation Finance
Office of Healthcare & Insurance
cc: James Pennington